Page 220 - Remedial Andrology

1026. Ozturk, U., et al. Effects of sildenafil treatment on patients with Peyronie’s disease and erectile
dysfunction. Ir J Med Sci, 2014. 183: 449.
https://pubmed.ncbi.nlm.nih.gov/24190613
1027. Mulhall, J.P., et al. Peyronie’s disease cell culture models: phenotypic, genotypic and functional
analyses. Int J Impot Res, 2002. 14: 397.
https://pubmed.ncbi.nlm.nih.gov/12454692
1028. Roth, M., et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular
matrix. Proc Natl Acad Sci U S A, 1996. 93: 5478.
https://pubmed.ncbi.nlm.nih.gov/8643600
1029. Favilla, V., et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil
in Peyronie’s disease: preliminary results from a prospective, double-blinded, randomized study.
Andrology, 2017. 5: 771.
https://pubmed.ncbi.nlm.nih.gov/28718527
1030. Abern, M.R., et al. Combination of penile traction, intralesional verapamil, and oral therapies for
Peyronie’s disease. J Sex Med, 2012. 9: 288.
https://pubmed.ncbi.nlm.nih.gov/22024053
1031. Rehman, J., et al. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term
single-blind study. Urology, 1998. 51: 620.
https://pubmed.ncbi.nlm.nih.gov/9586617
1032. Soh, J., et al. Nicardipine vs. saline injection as treatment for Peyronie’s disease: a prospective,
randomized, single-blind trial. J Sex Med, 2010. 7: 3743.
https://pubmed.ncbi.nlm.nih.gov/20584114
1033. Toscano, L., Jr., et al. A prospective, randomized, single - blind study comparing intraplaque
injection of thiocolchicine and verapamil in Peyronie’s Disease: a pilot study. Int Braz J Urol, 2016.
42: 1005.
https://pubmed.ncbi.nlm.nih.gov/24893912
1034. Shirazi, M., et al. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized
single-blind, placebo-controlled study. Int Urol Nephrol, 2009. 41: 467.
https://pubmed.ncbi.nlm.nih.gov/19199072
1035. Gelbard, M.K., et al. The use of collagenase in the treatment of Peyronie’s disease. J Urol, 1985.
134: 280.
https://pubmed.ncbi.nlm.nih.gov/2991611
1036. Ehrlich, H.P. Scar contracture: cellular and connective tissue aspects in Peyronie’s disease. J Urol,
1997. 157: 316.
https://pubmed.ncbi.nlm.nih.gov/8976288
1037. Gelbard, M.K., et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-
blind study. J Urol, 1993. 149: 56.
https://pubmed.ncbi.nlm.nih.gov/8417217
1038. Jordan, G.H. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease:
a prospective, single-center, non-placebo-controlled study. J Sex Med, 2008. 5: 180.
https://pubmed.ncbi.nlm.nih.gov/18173766
1039. EMA, Assessement Report - Xiapex (Collagenase Clostridium Histolyticum). 2014.
https://www.ema.europa.eu/en/documents/variation-report/xiapex-h-c-2048-ii-0044-epar-
assessment-report-variation_en.pdf
1040. Russo, G.I., et al. Comparative Effectiveness of Intralesional Therapy for Peyronie’s Disease in
Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis. J Sex Med, 2019. 16:
289.
https://pubmed.ncbi.nlm.nih.gov/30692028
1041. Lipshultz, L.I., et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of
Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-
controlled, phase III studies. BJU Int, 2015. 116: 650.
https://pubmed.ncbi.nlm.nih.gov/25711400
1042. Gelbard, M., et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for
the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3
studies. J Urol, 2013. 190: 199.
https://pubmed.ncbi.nlm.nih.gov/25711400
1043. Levine, L.A., et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection
in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med, 2015. 12: 248.
https://pubmed.ncbi.nlm.nih.gov/25388099

SEXUAL AND REPRODUCTIVE HEALTH - MARCH 2021 219